


In vivo study in collaboration with Professor REVUZ from Mondor Hospital

Profilometry and image analysis - 2 and 4-month study versus placebo

Two groups of 30 volunteers / Twice-daily application on the face and décolleté for 4 months of a cream containing 5% MATRIXYL for one group and a placebo for the other / Image analysis by profilometry on Silflo® prints at T0, T2 and T4 months. Biopsies on 12 volunteers.

Clinical study:



Biopsies :

ELASTIN			COLLAGEN IV	
T0	T4 months	Results	T4 months	Results
MATRIXYL		Notable increase of density and thickness of fibres.	MATRIXYL	
Excipient		No change	Excipient	

MATRIXYL, which peptide belongs to the family of Matrikines (Peptidic fragments, messengers of the natural process of tissue repair), is designed to replace retinol and its esters as an efficient anti-wrinkle active ingredient. It acts through specific mechanisms, without any toxicological danger.

MATRIXYL equals and exceeds retinol activity. It can be incorporated in any skin care product, all over the world.



Sederma
29 rue du Chemin Vert
78612 Le Perray-en-Yvelines Cedex France

Tel. : +33 (0)1 34 84 10 10
Fax : +33 (0)1 34 84 11 30

E-mail: sederma@sederma.fr
Web: www.sederma.fr